Rafael (RFL) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rafael (RFL) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 25.8% versus a loss of 85.2%. Over five years, RFL leads with a -84.2% price change compared with -100.0% for TNXP. Rafael is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs -4.7%).
Tonix Pharmaceuticals converts more of its revenue into profit, with a net margin of -946.2% versus -3390.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RFL | TNXP |
|---|---|---|
| Share price | $0.9197 | $2.38 |
| Market cap | $47.99M | $46.25M |
| 1-day change | +2.19% | -6.67% |
| YTD return | -22.06% | -84.76% |
| 1-year return | -25.83% | -85.22% |
| 5-year return | -84.19% | -100.00% |
| EPS (TTM) | $-0.58 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.00K | $13.11M |
| Revenue growth (YoY) | -4.69% | +29.85% |
| Net income (latest FY) | $-29.64M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | -3822.54% | -959.05% |
| Net margin | -3390.73% | -946.22% |
| 52-week high | $3.96 | $20.56 |
| 52-week low | $0.781 | $2.30 |
| Distance from 52-week high | -76.78% | -88.42% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1769.75% |
| Average volume | 140.84K | 838.83K |
| Shares outstanding | 51.39M | 19.43M |
| Employees | 21 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed TNXP by 59.4 percentage points over the past year.
- Tonix Pharmaceuticals is more profitable, keeping -946.2 cents of every revenue dollar as net income versus -3390.7 cents for Rafael.
- Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs -4.69%).
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
RFL vs TNXP FAQ
Which is bigger, Rafael or Tonix Pharmaceuticals?
Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.25M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, RFL or TNXP?
RFL returned -25.83% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Rafael and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.